# Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit

> **NIH NIH UM1** · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $4,228,318

## Abstract

DESCRIPTION (provided by applicant): The Weill Cornell Medical College - New Jersey Medical School Clinical Trials Unit (WCMC-NJMS CTU) will conduct National Institute of Allergy and Infectious Diseases (NIAID)-sponsored network studies of HIV treatment and HIV prevention and enroll participants from communities of the New York City (NYC)-Newark metropolitan area, the epicenter of HIV in the U.S. The unit consists of a central core and three clinical research sites (CRS). The WCMC-NJMS CTU provides central research support to the three CRS, including investigative oversight; financial administration; coordination of laboratories, pharmacy, regulatory assurance, data management, quality assurance, training; and community engagement. The three CRS, WCMC-Uptown, WCMC-Chelsea, and NJMS-Newark are located in different parts of the NYC-Newark metropolitan area and serve distinct, racially and ethnically diverse patient populations of HIV-infected and at-risk individuals. WCMC-Uptown CRS is located close to Harlem, a neighborhood with an HIV seroprevalence rate of nearly 3%. The WCMC-Chelsea CRS is located in Chelsea, the neighborhood with the highest HIV seroprevalence rate in NYC of over 4%. The NJMS-Newark CRS is located in the center of Newark, and serves a predominately African American population with a seroprevalence of 3%. WCMCNJMS CTU investigators are leaders in the field who are shaping the HIV treatment and HIV prevention research agendas. They are highly experienced with expertise in non-infectious complications of HIV; HCV studies of both mono- and co-infected individuals; tuberculosis, including cutting-edge diagnostics; HIV related malignancies; novel antiretrovirals; and HIV prevention, including studies of pre-exposure prophylaxis (PrEP) to prevent HIV acquisition. Community engagement is a key strength of the WCMC-NJMS CTU with both site-specific and joint Community Advisory Boards (CAB), and a strong record of effectively communicating study results back to the community. In summary, the WCMC-NJMS CTU brings together a diverse group of recognized investigator leaders who will work with an experienced clinical research staff to conduct cutting-edge HIV treatment and HIV prevention studies in the NYC-Newark metropolitan area.    
   
RELEVANCE:  Over 1 million Americans currently are living with HIV infection and 50,000 Americans are newly infected with HIV each year. The New York City - Newark metropolitan area is the most affected area of the U.S. with over 100,000 people living with HIV infection and over 3500 newly infected with HIV each year. The WCMC-NJMS CTU will conduct studies of HIV treatment and HIV prevention to advance the field.

## Key facts

- **NIH application ID:** 9824554
- **Project number:** 5UM1AI069419-14
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** ROY M. GULICK
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $4,228,318
- **Award type:** 5
- **Project period:** 2007-01-10 → 2020-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9824554

## Citation

> US National Institutes of Health, RePORTER application 9824554, Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit (5UM1AI069419-14). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/9824554. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*